Login to Your Account


TAIPEI, Taiwan – Calling its recent FDA orphan designation for small-molecule drug CX-4945 in cholangiocarcinoma an important milestone, 2012 startup Senhwa Biosciences Inc. enters 2017 with plans for an uplisting on the Taiwan stock exchange.

LONDON – Following a total corporate makeover and a revamp of its technology, Realm Therapeutics plc has announced its rebirth with the filing of an FDA IND for a phase II study of its lead product, PRO22.

Avexxin AS is a testament to perseverance. Over several decades, Berit Johansen, the company's chief scientific officer, conducted basic research into the chronic inflammatory process.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: